

1 **Spatial and Temporal Distribution of Visceral Leishmaniasis in Karamoja Region,**
2 **Uganda: Analysis of surveillance data, 2015–2022**

3 **Authors:** Mercy Wendy Wanyana^{1*}, Richard Migisha¹, Patrick King¹, Benon Kwesiga¹,
4 Daniel Kadobera¹, Lilian Bulage¹, Alex Riolexus Ario¹

5 **Institutional affiliations:** ¹Uganda Public Health Fellowship Program, Uganda National
6 Institute of Public Health, Kampala, Uganda

7 ***Correspondence:** Email: mwanyana@uniph.go.ug, Tel: +256779207928

8
9

10 **Abstract**

11
12 **Background:** Uganda targets to control leishmaniasis and eliminate visceral
13 leishmaniasis as a public health problem by 2030, with 85% of the cases detected, 95%
14 treated, and visceral leishmaniasis eliminated (<1% case fatality rate [CFR]). However,
15 little is documented on the country's progress towards achieving these targets. We
16 examined the temporal trends and spatial distribution of leishmaniasis in the endemic
17 Karamoja Region of Uganda, 2015–2022.

18 **Methods:** We analysed aggregate secondary data on clinically diagnosed leishmaniasis
19 laboratory-confirmed cases, visceral leishmaniasis cases, hospital admissions, and
20 deaths from the District Health Information System 2. We used population-based
21 calculations to determine the annual prevalence of leishmaniasis and quarterly
22 prevalence of visceral leishmaniasis per 1,000,000 persons, while the prevalence of
23 leishmaniasis admissions and CFRs were calculated per 100 cases. We used the
24 Mann-Kendall test to assess the significance of the trend.

25 **Results:** Overall, 4,008 cases of clinically diagnosed leishmaniasis were reported, and
26 of these, 11% were laboratory-confirmed. The average annual prevalence of
27 leishmaniasis was 4 per 1,000,000 population. From 2020 to 2022, there was an
28 increasing trend in quarterly prevalence of visceral leishmaniasis (Kendall's score=36,
29 p=0.016), averaging 3 cases per 1,000,000 population. Leishmaniasis admissions
30 increased annually to 55 per 100 cases (Kendall's score=23, p=0.006). The average
31 annual CFR was 5%, with no deaths reported in 2018, 2019, and 2021. Amudat District
32 had the highest prevalence rates of leishmaniasis (477 per 1,000,000 population) and
33 visceral leishmaniasis (139 per 100,000 population).

34 **Conclusion:** The increasing trend of visceral leishmaniasis, and CFR >1% threaten the
35 goal of controlling leishmaniasis as a public health problem by 2030. Gaps in case
36 detection may further prevent the achievement of targets. Strengthening existing
37 interventions, such as vector control and rapid diagnostic kits for early detection and
38 treatment, may be crucial to sustain progress toward elimination targets.

39

40 **Keywords:** Leishmaniasis, Visceral leishmaniasis, Disease control, Uganda

41

43 Background

44 Leishmaniasis is a vector-borne neglected tropical disease caused by a protozoan and
45 transmitted by a female sand fly mainly of *Phlebotomus* species¹. Transmission occurs
46 when an infected female sand fly bites a human host and transmits the parasite to the
47 host during its blood meal². The disease clinically manifests in three forms: cutaneous,
48 mucocutaneous and visceral³. Clinical presentation usually depends on the virulence of
49 the parasite, the individual's immunity, and the site of the lesion⁴. The cutaneous form is
50 the mildest form, typically presenting with painless nodules, macules, papules or
51 ulcerative lesions on the skin in areas exposed to bites of the sand fly. It is commonly
52 linked to the *Leishmania major* and *Leishmania tropica* species². The mucosal form
53 typically presents with lesions on the mucus membranes and cartilage in the nose,
54 mouth, upper respiratory tract, and pharynx⁵. Visceral leishmaniasis manifests as fever,
55 weight loss, splenomegaly, hepatomegaly, and reduced blood cell production,
56 potentially causing anemia, bleeding, and susceptibility to other infections^{6,7}. Visceral
57 Leishmaniasis, often associated with *L. donovani* in East Africa, is highly fatal with a
58 95% untreated case fatality rate and 10-20% with treatment^{8,9}. It carries outbreak
59 potential, with sequelae like relapse and post-kala-azar dermal leishmaniasis,
60 contributing to interepidemic reservoirs and sustaining transmission.

61
62 As of 2019, approximately 4,580,000 cases of leishmaniasis were reported globally,
63 causing an estimated 657,000 new cases annually and resulting in 697,000 Disease
64 Adjusted Life Years (DALYs) lost¹⁰. African countries including Uganda contribute a
65 significant proportion of the burden, accounting for 34-57%¹¹. Leishmaniasis
66 disproportionately impacts the poorest populations due to factors such as inadequate
67 housing, poor environmental sanitation, lack of control measures, and economically
68 driven migration to vector-prone areas, increasing their susceptibility to the disease^{12,13}.
69 Children and immunocompromised individuals, including People Living with HIV
70 (PLWHIV), are more affected than adults and non-immunocompromised individuals^{14,15}.

71
72 Leishmaniasis places a catastrophic financial burden on affected households with a
73 median cost ranging from USD 165 to 1,500 per episode^{13,16}. To avert this burden,
74 current global efforts aim at controlling leishmaniasis and eliminate leishmaniasis by
75 2030 through the World Health Organization (WHO) Roadmap for neglected tropical
76 diseases 2021–2030¹⁷. Specifically, this aims to ensure that 85% of all leishmaniasis
77 cases are detected, 95% treated, and visceral leishmaniasis eliminated (<1% case
78 fatality rate [CFR]); this includes Uganda where the disease is endemic especially in the
79 Karamoja Region. Currently there is a paucity of data on the country's progress and
80 burden of leishmaniasis. This could be attributed to the limited analysis of surveillance
81 data despite it's being in the national integrated disease surveillance system.¹⁸ Analysis
82 of the surveillance data is key to detect remaining or re-emerging hotspots of
83 leishmaniasis transmission which supports timely adaptation of control and elimination
84 interventions¹⁹. Given the complexity of leishmaniasis management and diagnostics,
85 control efforts adopt an innovative and intensified disease management approach,
86 emphasizing individual care at health facilities²⁰. As such, understanding trends in
87 health facility leishmaniasis data is crucial for evidence-based decision-making. We

88 examined the temporal trends and spatial distribution of leishmaniasis in the endemic
89 Karamoja Region of Uganda, 2015–2022.

90 **Methods**

91 **Study settings**

92 We utilised leishmaniasis surveillance data generated from all health facilities in the
93 Karamoja region in the years 2015–2022. Leishmaniasis is endemic in the Karamoja
94 region in Uganda. The semi-arid climate and termite hills in this region provide a
95 favourable environment for sand flies of *Phlebotomus* species which are the vector
96 responsible for transmission of Visceral Leishmaniasis²¹. Within Uganda health facilities
97 leishmaniasis is diagnosed clinically and confirmed using a Giemsa-stain slides viewed
98 under a microscope.

99 **Study design and data Source**

100 We conducted a descriptive study using routinely collected leishmaniasis surveillance
101 data collected in District Health Information System 2 (DHIS-2). The DHIS-2 collects
102 data on diseases of public health importance like leishmaniasis based on the Integrated
103 Disease Surveillance and response guidelines.²² It includes data on both clinically
104 diagnosed and laboratory confirmed leishmaniasis cases, admissions, primary visceral
105 leishmaniasis i.e. without history of visceral leishmaniasis treatment, relapse i.e. with
106 history of visceral leishmaniasis treatment, post-kala-azar dermal leishmaniasis, a
107 complication of visceral leishmaniasis and leishmaniasis HIV co-infection, and deaths.
108 Before 2020, all forms of leishmaniasis (cutaneous, visceral and mucosal) were
109 reported jointly in the monthly outpatient and in-patient registers. In 2020, an in-patient
110 tool that collects primary visceral leishmaniasis, relapse and leishmaniasis HIV co-
111 infection was introduced. In this study, we utilized aggregate data of on leishmaniasis
112 from monthly outpatient reports (Health Management Information System forms [HMIS]
113 105) 2015–2022, inpatient monthly reports (HMIS 108) 2015–2022, and (HMIS 127b)
114 2020–2022.

115 **Study variables, data management, and analysis**

116 We downloaded the data regarding clinically-diagnosed and laboratory-confirmed
117 leishmaniasis cases and admissions, primary visceral leishmaniasis, relapse visceral
118 leishmaniasis, post-kala-azar dermal leishmaniasis, and visceral leishmaniasis HIV co-
119 infection, and death.in excel and imported in STATA version 16 software (StataCorp,
120 College Station, Texas, USA) for analysis. Using data on leishmaniasis and visceral
121 leishmaniasis cases, we calculated the annual prevalence of leishmaniasis as
122 laboratory confirmed leishmaniasis cases divided by the population in the region. From
123 2020 to 2022, we assessed the proportions of primary, relapse, post-kala-azar dermal
124 leishmaniasis, and HIV co-infection among admitted Visceral Leishmaniasis cases.
125 Quarterly prevalence of Visceral Leishmaniasis was calculated as the ratio of primary
126 and relapse cases to the population, obtained from Uganda Bureau of Statistics.
127 Leishmaniasis admissions and hospitalization prevalence were determined using

128 leishmaniasis cases as denominators. Case fatality rates were computed based on the
129 proportion of deceased leishmaniasis cases. Line graphs were used to show trends,
130 and Mann-Kendall test to assess the significance of trends. We used choropleth maps
131 created with QGIS software to illustrate the spatial distribution of leishmaniasis in the
132 region.

133 **Ethical Considerations**


134 Our study utilized routinely generated aggregated surveillance data with no personal
135 identifiers in health facility outpatient and in-patient monthly reports, obtained from the
136 DHIS-2. The Uganda Public Health Fellowship Program is part of the National Rapid
137 Response Team, and has been granted permission to access and analyse surveillance
138 data in the DHIS-2 and other data such as survey and field investigation data to inform
139 decision making in the control and prevention of outbreaks and public health
140 programming. Additionally, the Ministry of Health (MoH) has also granted the program
141 permission to disseminate the information through scientific publications. We stored the
142 abstracted data set in a password-protected computer and only shared it with the
143 investigation team. In addition, the Office of the Associate Director for Science, U.S.
144 Centers for Disease Control and Prevention, determined that this study was not a
145 human subjects research with the primary intent of improving use of surveillance data to
146 guide public health planning and practice.

147 This activity was reviewed by CDC and was conducted consistent with applicable
148 federal law and CDC policy. §
149 §See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44
150 U.S.C. §3501 et seq.
151

152 **Results**

153 **Trends in the prevalence of leishmaniasis, Karamoja Region, Uganda, 2015-2022**

154 Reporting rates for the Karamoja region ranged from 96% to 100% during the review
155 period (from 2015 to 2022). Overall, 4,008 clinically-diagnosed leishmaniasis cases were
156 reported. Of these, 484 (11%) were confirmed. The average annual prevalence of
157 leishmaniasis was 4 cases per 1,000,000 population in the Karamoja Region reported
158 from 2015 to 2022. No trend in leishmaniasis prevalence was observed, Kendall's score=
159 13, $p=0.173$ (Figure 1).




160

161 **Figure 1: Trends in annual leishmaniasis prevalence, Karamoja Region, Uganda,**
162 **2015–2022**

163

164 **Trends of the quarterly prevalence of visceral leishmaniasis, Karamoja Region,**
165 **Uganda, 2020–2022**

166 Over the review period, 602 visceral leishmaniasis cases were reported. Of these 540
167 (90%) were primary visceral leishmaniasis cases while 62 (10%) were relapse cases. Of
168 the total cases, 4 (1%) were visceral leishmaniasis HIV-coinfected and 5 (1%) were
169 post-kala-azar dermal leishmaniasis. The average quarterly prevalence of visceral
170 leishmaniasis cases was 3 cases per million with the highest prevalence (5 cases per
171 1,000,000 population) reported in the quarter 3 of 2022 (Figure 2). From 2020 to 2022,
172 there was an increasing trend in the quarterly prevalence of visceral leishmaniasis,
173 Kendall's score=36, $p=0.016$.




174

175 **Figure 2: Trends in quarterly prevalence of visceral leishmaniasis, Karamoja**
176 **Region, Uganda, 2020–2022.**

177 **Trends of leishmaniasis admissions, Karamoja Region, Uganda, 2015–2022**

178 From 2015 to 2022, the average annual prevalence of leishmaniasis admission in the
179 Karamoja region was 52 cases per 100 cases. The highest incidence of leishmaniasis
180 admissions were reported in the years 2020 (87 leishmaniasis admissions per 100
181 cases), 2021 (93 leishmaniasis admissions per 100 cases), and 2022 (92 leishmaniasis
182 admissions per 100 cases) (Figure 3). Overall there was an increasing trend of
183 leishmaniasis admissions, Kendall's score= 23, p=0.006.



184


185 **Figure 3: Trends in hospital admissions due to leishmaniasis in Karamoja Region,**
186 **Uganda, 2015–2022.**

187

188 **Leishmaniasis case fatality rate, Karamoja region, Uganda, 2015–2022**

189 During the review period, the average annual CFR was 5% (Range: 0-11%), with no
190 deaths reported in 2018, 2019, and 2021. The highest case fatality rates was recorded in
191 2020. No trends were observed in the case fatality rate, Kendall's score= -2, p=0.947
192 (Figure 4).

193




194


195 **Figure 4: Trends in leishmaniasis case fatality rate, Karamoja Region, Uganda,**
196 **2015–2022**

197 **Spatial distribution of Leishmaniasis, Karamoja Region, Uganda, 2015–2022**

198 Within the Karamoja Region, Amudat District reported the highest average annual
199 prevalence of both leishmaniasis (477 per 1,000,000 population) and visceral
200 leishmaniasis (139 per 100,000 population). Abim, Kaabong, Karenga, and Nabilatuk
201 did not report both leishmaniasis and visceral leishmaniasis cases during the reporting
202 period.

203





205

206 **Figure 5: Spatial distribution of leishmaniasis and visceral leishmaniasis,**
207 **Karamoja Region, Uganda, 2015–2022**

208

209 Discussion

210 In this analysis to examine the temporal trends and spatial distribution of leishmaniasis
211 in an endemic Karamoja Region of Uganda, 2015–2022, only 11% of the clinically-
212 diagnosed leishmaniasis cases were laboratory confirmed. Over the review period, no
213 changes were observed in the annual prevalence of leishmaniasis. While most visceral
214 leishmaniasis cases were primary, we identified relapse, post-kala-azar dermal
215 leishmaniasis, and visceral leishmaniasis HIV coinfecting cases between 2020 and
216 2022. A rising trend in quarterly prevalence of visceral leishmaniasis occurred from
217 quarter one (Q1) 2020 to quarter four (Q4) 2022, along with an increase in hospital
218 admissions due to leishmaniasis. The average annual CFR remained <1%, with no
219 deaths reported in 2018, 2019, and 2021. Amudat District had the highest leishmaniasis
220 prevalence.

221

222 We identified gaps in case detection, with only 11% of clinically-diagnosed cases
223 confirmed by laboratory investigations. Leishmaniasis shares clinical features with
224 common regional illnesses like malaria, typhoid, and tuberculosis, emphasizing the
225 importance of laboratory confirmation in case detection²³. In the East African region,
226 numerous factors may hinder laboratory confirmation for leishmaniasis including low
227 proportions of health facilities with microscopes and microscopy supplies and trained
228 staff in leishmaniasis testing²⁴. Such existing gaps may hinder achievement of
229 leishmaniasis targets of 85% of all leishmaniasis cases detected.

230

231 In contrast to the global declining trends in leishmaniasis prevalence, no significant
232 trends were observed in the Karamoja Region for leishmaniasis cases from 2015 to

233 2022^{25,26}. The Karamoja Region like the rest of East Africa faces unique challenges that
234 may prevent declines despite targets. The Karamoja Region like the rest of East Africa
235 faces unique challenges that may prevent declines despite targets, including poor at-
236 risk population with limited access to healthcare and insecurity in endemic regions¹⁹.
237 Our findings further indicated an increase in the quarterly prevalence of visceral
238 leishmaniasis cases from 2020 to 2022. This trend is similar to global leishmaniasis
239 surveillance data that indicated an increase in visceral leishmaniasis in the East African
240 Region during 2020¹¹. During this period, vital control programs supporting the region,
241 such as the Accelerating the Sustainable Control and Elimination of Neglected Tropical
242 Diseases, were terminated. This resulted in the scaling down of control efforts²⁷. The
243 increase in visceral leishmaniasis cases following termination of control programmes
244 may undo previous gains towards achievement of elimination targets. Furthermore, we
245 found Visceral Leishmaniasis relapse and post-kala-azar dermal leishmaniasis (PKDL)
246 cases. The presence of these cases contributes to the maintenance of infectious
247 reservoirs, posing a threat to the achievement of elimination targets²⁸.

248 Our findings revealed a considerable number of hospital admissions due to
249 leishmaniasis. This suggests a sustained burden of visceral leishmaniasis whose illness
250 and management often requires hospitalisation²⁹. Admissions due to leishmaniasis
251 impose a substantial economic burden on households, with a median expenditure of
252 450 US dollars per hospital stay due to leishmaniasis³⁰. We found that hospital
253 admissions linked to leishmaniasis increased. This might suggest gaps in treatment of
254 leishmaniasis resulting in leishmaniasis complications that may require in-patient
255 admissions.

256 The average annual CFR was still greater than the 1% target by 2030. This indicated
257 that Uganda is yet to achieve the control leishmaniasis and eliminate visceral
258 leishmaniasis as a public health elimination. The no trend observed in CFR and its
259 substantial variation in the CFR from 0 to 11% suggests a need for intensifying efforts to
260 ensure targets are met. Such efforts include improving prompt diagnosis of visceral
261 leishmaniasis using rapid diagnostic kits and increasing access to prompt effective
262 treatment.

263 In regards to the current distribution, Amudat had the highest prevalence of both
264 leishmaniasis and visceral leishmaniasis. This pattern may be attributed to presence of
265 a referral leishmaniasis treatment centre at Amudat Hospital³¹.

266 Our findings should be interpreted with considerations of the following limitations. Our
267 use of facility-based data may lead to an underestimation of the true disease burden,
268 capturing only individuals seeking healthcare. Previous studies have indicated that
269 surveillance data may underreport the burden of leishmaniasis up to 8 fold for visceral
270 leishmaniasis and 5 fold for cutaneous leishmaniasis⁹. Additionally, our reliance on
271 aggregate data restricted further exploration of prevalence in population subcategories
272 and specific clinical types of leishmaniasis.

273 **Conclusion**

274 The current burden of leishmaniasis coupled with gaps in case detection threatens the
275 achievement of control of leishmaniasis targets. While the increasing trends of visceral
276 leishmaniasis and variation in case fatality rates question whether achieved visceral
277 leishmaniasis targets will be met by 2030. Existing interventions should be intensified to
278 including vector control, rapid diagnostic kits for early detection and prompt treatment
279 should be intensified to sustain the achievement of elimination targets.

280

281 **List of abbreviations**

282 CFR: Case Fatality Rate
283 DHIS-2: District Health Information System 2
284 HMIS: Health Management Information System
285 NTD: Neglected Tropical Disease
286 PKDL: Post-kala-azar Dermal Leishmaniasis

287

288

289

290

291

292

293

294 Acknowledgements

295 We would like to thank the Ministry of Health for providing access to DHIS2 data that
296 was used for this analysis. We appreciate the technical support provided by the Division
297 of Surveillance, Information and Knowledge Management and the Division of Vector
298 Control. Finally, we thank the US-CDC for supporting the activities of the Uganda Public
299 Health Fellowship Program.

300

301 References

- 302 1. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R.
303 Leishmaniasis: a review. *F1000Research*. 2017;6:750.
- 304 2. Bates PA. Transmission of *Leishmania* metacyclic promastigotes by phlebotomine
305 sand flies. *Int J Parasitol*. 2007 Aug;37(10):1097–106.
- 306 3. Burza S, Croft SL, Boelaert M. Leishmaniasis. *Lancet* (London, England). 2018
307 Sep;392(10151):951–70.
- 308 4. Mokni M. [Cutaneous leishmaniasis]. *Ann Dermatol Venereol*. 2019
309 Mar;146(3):232–46.
- 310 5. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and
311 mucocutaneous leishmaniasis: Clinical perspectives. *J Am Acad Dermatol*
312 [Internet]. 2015 Dec 1;73(6):897–908. Available from:
313 <https://doi.org/10.1016/j.jaad.2014.08.051>
- 314 6. Bi K, Chen Y, Zhao S, Kuang Y, John Wu C-H. Current Visceral Leishmaniasis
315 Research: A Research Review to Inspire Future Study. *Biomed Res Int*.
316 2018;2018:9872095.
- 317 7. van Griensven J, Diro E. Visceral leishmaniasis. *Infect Dis Clin North Am*. 2012
318 Jun;26(2):309–22.
- 319 8. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral
320 leishmaniasis: what are the needs for diagnosis, treatment and control? *Nat Rev*
321 *Microbiol* [Internet]. 2007;5(11):873–82. Available from:
322 <https://doi.org/10.1038/nrmicro1748>
- 323 9. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis
324 worldwide and global estimates of its incidence. *PLoS One*. 2012;7(5):e35671.
- 325 10. IHE (Institute for Health Metrics and Evaluation). Leishmaniasis- Level 3 Cause
326 [Internet]. 2019 [cited 2023 Feb 1]. Available from:
327 [https://www.healthdata.org/results/gbd_summaries/2019/leishmaniasis-level-3-](https://www.healthdata.org/results/gbd_summaries/2019/leishmaniasis-level-3-cause)
328 [cause](https://www.healthdata.org/results/gbd_summaries/2019/leishmaniasis-level-3-cause)
- 329 11. mondiale de la Santé O, Organization WH. Global leishmaniasis surveillance:
330 2019–2020, a baseline for the 2030 roadmap—Surveillance mondiale de la
331 leishmaniose: 2019-2020, une période de référence pour la feuille de route à

- 332 l'horizon 2030. *Wkly Epidemiol Rec Relev Épidémiologique Hebd.*
333 2021;96(35):401–19.
- 334 12. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. *Trends Parasitol.* 2006
335 Dec;22(12):552–7.
- 336 13. Okwor I, Uzonna J. Social and Economic Burden of Human Leishmaniasis. *Am J*
337 *Trop Med Hyg.* 2016 Mar;94(3):489–93.
- 338 14. Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT. Visceral leishmaniasis and
339 HIV coinfection: current perspectives. *HIV AIDS (Auckl).* 2018;10:193–201.
- 340 15. Gupta AK, Singh A, Srivastava S, Shankar P, Singh S. Visceral Leishmaniasis in
341 children: Diagnosis, treatment, and prevention. *J Pediatr Infect Dis.*
342 2017;12(04):214–21.
- 343 16. Uranw S, Meheus F, Baltussen R, Rijal S, Boelaert M. The Household Costs of
344 Visceral Leishmaniasis Care in South-eastern Nepal. *PLoS Negl Trop Dis*
345 [Internet]. 2013 Feb 28;7(2):e2062. Available from:
346 <https://doi.org/10.1371/journal.pntd.0002062>
- 347 17. Casulli A. New global targets for NTDs in the WHO roadmap 2021–2030. *PLoS*
348 *Negl Trop Dis* [Internet]. 2021 May 13;15(5):e0009373. Available from:
349 <https://doi.org/10.1371/journal.pntd.0009373>
- 350 18. MoH (Ministry of Health Uganda). Sustainability Plan for Neglected Tropical
351 Diseases Control Program [Internet]. Kampala, Uganda; 2020. Available from:
352 [http://library.health.go.ug/publications/neglected-tropical-diseases/sustainability-](http://library.health.go.ug/publications/neglected-tropical-diseases/sustainability-plan-neglected-tropical-diseases-control)
353 [plan-neglected-tropical-diseases-control](http://library.health.go.ug/publications/neglected-tropical-diseases/sustainability-plan-neglected-tropical-diseases-control)
- 354 19. Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis
355 as a public health problem in east Africa: reflections on an enhanced control
356 strategy and a call for action. *Lancet Glob Heal.* 2021 Dec;9(12):e1763–9.
- 357 20. Engels D, Zhou X-N. Neglected tropical diseases: an effective global response to
358 local poverty-related disease priorities. *Infect Dis Poverty* [Internet]. 2020;9(1):10.
359 Available from: <https://doi.org/10.1186/s40249-020-0630-9>
- 360 21. Jones CM, Welburn SC. Leishmaniasis Beyond East Africa. *Front Vet Sci.*
361 2021;8:618766.
- 362 22. MoH (Ministry of Health Uganda). National Technical Guidelines for Integrated
363 Disease Surveillance and Response Third Edition [Internet]. 2021. Available from:
364 [https://www.afro.who.int/sites/default/files/2021-09/2_Uganda_3rd_IDS_R_Tech](https://www.afro.who.int/sites/default/files/2021-09/2_Uganda_3rd_IDS_R_Tech_Guideline_PrintVersion_10Sep2021.pdf)
365 [Guideline_PrintVersion_10Sep2021.pdf](https://www.afro.who.int/sites/default/files/2021-09/2_Uganda_3rd_IDS_R_Tech_Guideline_PrintVersion_10Sep2021.pdf)
- 366 23. Thakur S, Joshi J, Kaur S. Leishmaniasis diagnosis: an update on the use of
367 parasitological, immunological and molecular methods. *J Parasit Dis Off organ*
368 *Indian Soc Parasitol.* 2020 Jun;44(2):253–72.
- 369 24. de Souza DK, Picado A, Bessell PR, Liban A, Wachira D, Mwititi D, et al.
370 Strengthening Visceral Leishmaniasis Diagnosis Capacity to Improve Access to

- 371 Care in Kenya: The Example of Marsabit County. *Front Trop Dis* [Internet].
372 2022;2. Available from:
373 <https://www.frontiersin.org/articles/10.3389/fitd.2021.809757>
- 374 25. Alatif H. Burden and Trends of Leishmaniasis over the last one Decade Across
375 the Globe: Trend Analysis of WHO Regions. *Integr J Med Sci* [Internet]. 2020;8.
376 Available from: <https://mbmj.org/index.php/ijms/article/view/295>
- 377 26. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global,
378 regional, and national disability-adjusted life-years (DALYs) for 359 diseases and
379 injuries and healthy life expectancy (HALE) for 195 countries and territories,
380 1990–2017: a systematic analysis for the Global Burden of Disease Study
381 2017. *Lancet* [Internet]. 2018 Nov 10;392(10159):1859–922. Available from:
382 [https://doi.org/10.1016/S0140-6736\(18\)32335-3](https://doi.org/10.1016/S0140-6736(18)32335-3)
- 383 27. Makoni M. New threats to visceral leishmaniasis control. *The Lancet Microbe*
384 [Internet]. 2021 Nov 1;2(11):e574. Available from: [https://doi.org/10.1016/S2666-](https://doi.org/10.1016/S2666-5247(21)00285-8)
385 [5247\(21\)00285-8](https://doi.org/10.1016/S2666-5247(21)00285-8)
- 386 28. Duthie MS, Goto Y, Ghosh P, Mondal D. Impact of sequelae of visceral
387 leishmaniasis and their contribution to ongoing transmission of *Leishmania*
388 *donovani*. *Pathog Dis*. 2019 Aug;77(6).
- 389 29. Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. *J Glob Infect Dis*.
390 2010 May;2(2):151–8.
- 391 30. Meheus F, Abuzaid AA, Baltussen R, Younis BM, Balasegaram M, Khalil EAG, et
392 al. The economic burden of visceral leishmaniasis in Sudan: an assessment of
393 provider and household costs. *Am J Trop Med Hyg*. 2013 Dec;89(6):1146–53.
- 394 31. Olobo-Okao J, Sagaki P. Leishmaniasis in Uganda: historical account and a
395 review of the literature. *Pan Afr Med J*. 2014;18:16.
- 396